These Estrogen-structure based molecules have the ability to kill cancer cells of all stages of breast cancer. Other existing estrogen-based or estrogenic anticancer molecule acts against estrogen receptor (ER)-expressing breast cancer cells only. So, this molecule is 'fit-for-all' breast cancerphenotypes, These molecules have anticancer effect against other ER-expressing cancer cells, such as ovarian carcinoma, melanoma, pancreatic cancer, It is orally administrable (whereas estrogenic, anti-breast cancer drug FaslodexTM is intramuscularly injectable only). Hence, it holds the promise to become the first oral breast cancerdrug developed from India
Indian Institute of Chemical Engineers
Acces sibility Controls